Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,837 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99 - NCT04902937Recruiting
Testing how added radiation may work by immune and tumor markers
This study looks at people with non-metastatic invasive breast cancer who are getting curative breast surgery followed by planned radiation (sometimes with other anti-cancer medicines). Researchers want to understand whether a patient’s age and certain immune/tumor blood features can predict how well radiation helps.
JenaAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT05874414RecruitingPhase 1/Phase 2
Combination therapy for advanced KRAS-mutated bile duct cancer
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT04697576RecruitingPhase 1
Flu vaccine injected into melanoma tumors for stage I-IV
This trial tests whether injecting a flu vaccine directly into melanoma tumors helps shrink them. It is for people with stage I to IV melanoma who have at least one tumor that can be injected.
Columbus, OhioAges 18–99 - NCT07243002Recruiting
Patient outcomes with ribociclib or abemaciclib for early breast cancer
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
LondonAges 18 years+ - NCT04953897RecruitingPhase 1
Oral decitabine for cancer patients with kidney problems
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
Houston, TexasAges 18 years+ - NCT04953910RecruitingPhase 1
Oral decitabine for cancers with liver problems
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Houston, TexasAges 18 years+ - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT04960839Recruiting
Preventive radiation to the other breast after breast cancer surgery
This study looks at whether “preventive” radiation to your other (opposite) breast can lower the chance of future breast cancer in people at higher genetic risk. You must have had surgery for early-stage breast cancer and agree to avoid removing the other breast and ovaries.
Jiangxi, JiangxiAges 30–70 - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT04991870RecruitingPhase 1
Early-stage immune cell therapy for recurrent grade 4 brain tumors
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Houston, TexasAges 12 years+ - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT04995003RecruitingPhase 1
HER2 CAR T plus pembrolizumab for advanced HER2 sarcoma
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
Houston, TexasAges 1–25 - NCT05029791Recruiting
Study of immune markers in treated metastatic melanoma
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
LyonAges 18 years+ - NCT05033301Recruiting
Nurse Ned Clinic support for prostate cancer survivors
This study tests a nurse-led clinic (“Nurse Ned Clinic”) to see how well it supports men after curative (potentially curative) prostate cancer treatment. It may help you manage follow-up care during survivorship if you are at low risk of cancer coming back.
Toronto, OntarioAges 18 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+ - NCT05064280RecruitingPhase 2
Pembrolizumab plus lenvatinib for brain metastases from solid tumors
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
Houston, TexasAges 18 years+ - NCT05066139Recruiting
Study of older adults with digestive cancer
This study checks how well different care plans work for people age 75 and older who have digestive cancer and are about to start chemotherapy or targeted therapy. The goal is to improve treatment support and outcomes by doing a detailed, multidisciplinary evaluation.
StrasbourgAges 75 years+ - NCT05083754RecruitingPhase 1
New glioblastoma trial testing immune drug plus radiation
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Baltimore, MarylandAges 18–100 - NCT05097625Recruiting
Testing early detection of head and neck cancer relapse
This study aims to find signs of head and neck cancer coming back early, using scans/tests after you’ve had radical treatment. If you’re at higher risk and HPV-negative, this may help doctors catch relapse sooner.
LondonAges 18 years+ - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,837 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.